(Redirected from Lasix)
- Type: Diuretic
- Dosage Forms:20, 40, 80
- Common Trade Names: Lasix
- Approximately 50% bioavailability, so converting from oral to IV dose doubles oral dose
- Furosemide absorption may be reduced in decompensated CHF
- Fluid overload: Typically 40 mg IV or normal PO dosage IV
- hypertension: 10-40 mg PO QDAY-BID, max 600 mg/day
- Hypercalcemia: 120 mg/day PO divided QDAY - TID
- Continuous infusion may increase diuresis effect and minimize post-diuretic sodium retention and "diuretic braking"
- Start 0.1 mg/kg/hr, increase hourly to max of 0.75 mg/kg/hr
- Target > 1 mL/kg/hr
- Monitor for ototoxicity
- Hypercalcemia: 25-50mg IV q4h
- Pregnancy Rating:C
- Lactation: safety unknown
- Renal Dosing
- Adult: no adjustment, contraindicated in anuria
- Pediatric: no adjustment, contraindicated in anuria
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
- Allergy to class/drug
- electrolyte imbalances
- metabolic alkalosis
- hemolytic anemia
- steven-johnson syndrome
- urinary frequency
- muscle cramping
- blurred vision
- Half-life: 30-60 min
- Metabolism: liver minimally
- Excretion: urine
- Mechanism of Action: inhibits loop of henle and proximal and distal convoluted tubule sodium and chloride resorption
- Asare K. Management of Loop Diuretic Resistance in the Intensive Care Unit. Am J Health Syst Pharm. 2009;66(18):1635-1640.
- Vasko MR, Brown-Cartwright D, Knochel JP et al. Furosemide absorption is altered in decompensated congestive heart failure. Ann Intern Med. 1985; 102: 314–8.
- Pivac N, Rumboldt Z, Sardelic S et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Int J Clin Pharmacol Res. 1998; 18:121–8.
- Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med. 1997; 25:1969–75.